Lorenza Landi
Overview
Explore the profile of Lorenza Landi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, et al.
Cancer Discov
. 2023 Apr;
13(7):1556-1571.
PMID: 37068173
Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose...
12.
Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, et al.
Future Oncol
. 2023 Mar;
18(40):4457-4464.
PMID: 36946237
Despite the positive results obtained by first-line chemoimmunotherapy in patients with metastatic non-small-cell lung cancer (NSCLC), only a few second-line options are available after disease progression. Combi-TED is a phase...
13.
Ceddia S, Landi L, Cappuzzo F
Int J Mol Sci
. 2022 Aug;
23(16).
PMID: 36012655
is the most frequently mutated oncogene identified in human cancers. Despite the numerous efforts to develop effective specific inhibitors against , this molecule has remained "undruggable" for decades. The development...
14.
Terrenato I, Ercolani C, Di Benedetto A, Gallo E, Melucci E, Casini B, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740637
The approval of osimertinib for adjuvant treatment of stage I-II-III -mutated NSCLC (early stage) represents a paradigm shift, raising the question of whether other genotype-matched therapeutics approved for advanced-stage NSCLC...
15.
DIncecco A, Cannita K, Martella F, DE Vico A, Zaccagna G, Landi L, et al.
J Thorac Dis
. 2022 May;
14(4):805-808.
PMID: 35572878
No abstract available.
16.
Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, et al.
Ther Adv Med Oncol
. 2022 Feb;
13:17588359211059873.
PMID: 35173816
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is...
17.
Finocchiaro C, Rota A, Barbieri V, Bettini A, Bianco R, Borra G, et al.
Transl Cancer Res
. 2022 Feb;
8(Suppl 1):S16-S22.
PMID: 35117061
Background: In the field of oncological assistance, nowadays we have to deal with a complex scenario where patients got used to obtain a huge amount of information through internet or...
18.
Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa F, Cappuzzo F, Landi L, et al.
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439215
The actual role of chemotherapy in vulvar cancer is undeniably a niche topic. The low incidence of the disease limits the feasibility of randomized trials. Decision making is thus oriented...
19.
Bronte G, Puccetti M, Petracci E, Landi L, Cravero P, Scodes S, et al.
Front Oncol
. 2021 May;
11:669839.
PMID: 34017688
Background: Current therapy for non-small-cell lung cancer (NSCLC) frequently includes immune checkpoint inhibitors, such as pembrolizumab, and programmed death ligand 1 (PD-L1) positivity is mandatory for its use in this...
20.
Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, et al.
Eur J Cancer
. 2021 May;
150:224-231.
PMID: 33934059
Background: We previously demonstrated the cumulative poor prognostic role of concomitant medications on the clinical outcome of patients with advanced cancer treated with immune checkpoint inhibitors, creating and validating a...